Based on the mechanism-of-action of crinecerfont, and the results of the pediatric CAHtalyst trial, what role might this option provide for pediatric patients with CAH?

Patricia Fechner, MD

Medical Director, DSD Program
Medical Director, CAH Program
Co-Director, Turner Syndrome Clinic
Seattle Children’s Hospital
Professor of Pediatrics
University of Washington School of Medicine
Seattle, WA